Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance.
Vormfelde
S V
SV
D001189:Aryl Hydrocarbon Hydroxylases; D001682:Biological Availability; D016572:Cyclosporine / Q000378:metabolism / Q000493:pharmacokinetics; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism* / Q000493:pharmacokinetics*; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D017410:Practice Guidelines as Topic; D017035:Pravastatin / Q000378:metabolism / Q000493:pharmacokinetics; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology; D012449:Safety; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000378:metabolism
D065607:Cytochrome P-450 Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; D016572:Cyclosporine; D003577:Cytochrome P-450 Enzyme System; C086276:cerivastatin; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; D001189:Aryl Hydrocarbon Hydroxylases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D039181:Steroid 16-alpha-Hydroxylase; D017035:Pravastatin